GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » EV-to-EBIT

Scinai Immunotherapeutics (Scinai Immunotherapeutics) EV-to-EBIT : -1.42 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Scinai Immunotherapeutics's Enterprise Value is $15.50 Mil. Scinai Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-10.91 Mil. Therefore, Scinai Immunotherapeutics's EV-to-EBIT for today is -1.42.

The historical rank and industry rank for Scinai Immunotherapeutics's EV-to-EBIT or its related term are showing as below:

SCNI' s EV-to-EBIT Range Over the Past 10 Years
Min: -21.26   Med: 0   Max: 67.11
Current: -1.42

During the past 12 years, the highest EV-to-EBIT of Scinai Immunotherapeutics was 67.11. The lowest was -21.26. And the median was 0.00.

SCNI's EV-to-EBIT is ranked worse than
100% of 444 companies
in the Biotechnology industry
Industry Median: 8.05 vs SCNI: -1.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Scinai Immunotherapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $17.23 Mil. Scinai Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-10.91 Mil. Scinai Immunotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -63.29%.


Scinai Immunotherapeutics EV-to-EBIT Historical Data

The historical data trend for Scinai Immunotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics EV-to-EBIT Chart

Scinai Immunotherapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -4.06 -48.57 -5.07 -1.34

Scinai Immunotherapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -1.34 -1.68 -2.03 -1.58

Competitive Comparison of Scinai Immunotherapeutics's EV-to-EBIT

For the Biotechnology subindustry, Scinai Immunotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's EV-to-EBIT falls into.



Scinai Immunotherapeutics EV-to-EBIT Calculation

Scinai Immunotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.501/-10.905
=-1.42

Scinai Immunotherapeutics's current Enterprise Value is $15.50 Mil.
Scinai Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics  (NAS:SCNI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Scinai Immunotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-10.905/17.2311791
=-63.29 %

Scinai Immunotherapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $17.23 Mil.
Scinai Immunotherapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Headlines

From GuruFocus

BiondVax Announces Closing of $8 Million Underwritten Public Offering

By Value_Insider Value_Insider 12-20-2022